

THE WEEKLY WRAP-UP

08th December 2017

DOMESTIC:

- Wipro to contest lawsuit filed by US utility firm
- Dr Reddy's Laboratories receives EIR from USFDA for Telangana unit
- Biocon receives USFDA nod for biosimilar
- Zee Learn may pick up 42.78% in MT Educare
- Artson Engineering bags Rs23cr order
- ONGC partners in 6 pre-NELP blocks may have to share cess, royalty load
- Tata Projects bags order worth Rs5,612cr
- Thai start-up DRVR partners with Tata Communications
- LancoInfratech seeks to sell four renewable assets
- Reliance Infrastructure secures two EPC contracts worth Rs5000cr
- Suven Life Sciences secures product patents in Eurasia and Norway
- Maharashtra land scam: IRB CMD, others charged
- L&T's Hydrocarbon Engineering arm awarded order worth Rs1,600cr
- Airtel, Vodafone keen to buy RCom's airwaves
- Infosys appoints Salil S. Parekh as CEO and Managing Director
- Airtel acquires stake in digital books platform

ECONOMY:

- FPIs Fitch Ratings cut India's FY18 GDP growth forecast to 6.7%
- RBI keeps repo rate unchanged at 6%, maintains neutral stance
- Agri experts pitch for income security for farmers in Budget
- Sugar off-take to increase soon; ISMA


INDUSTRY:

- Indian healthcare market to hit USD372bn by 2022
- Fertiliser subsidy arrear drops to Rs 23,000cr: Ananth Kumar
- India's economy will double to \$5 trillion by 2024: Mukesh Ambani
- Tata Motors global sales up 22% in November
- Gas from new north-eastern fields may fetch higher prices
- Exiting Kenya, Rwanda, Tanzania to help Airtel boost margins: Analysts

Price Performance (%)

Company	1M	3M	12M
Supreme Petrochem Ltd	1.4%	-5.3%	79.2%
Shanthi Gears Ltd	5.3%	2.4%	25.4%
Hind Rectifiers Ltd	7.2%	22.2%	29.5%
KCP Ltd	1.7%	0.7%	36.9%
Harita Seating System Ltd	-3.4%	16.2%	31.0%
Hester Biosciences Ltd	25.7%	54.6%	100.2%
Rallis India Ltd	3.5%	7.0%	15.4%
The Hi-Tech Gears Ltd	28.4%	41.8%	72.8%
Bharat Bijlee Ltd	10.0%	-2.4%	36.5%
Castrol India Ltd	0.8%	1.3%	-1.5%
TNPL	9.9%	9.5%	10.8%
Triveni Turbines Ltd	-3.4%	-2.2%	10.7%
Siemens Ltd	-4.3%	-8.4%	3.2%
Hikal Ltd	-2.5%	11.2%	7.8%
Aksh Optifibre Ltd	-7.5%	17.6%	26.6%
GMM Pfaunder Ltd	12.9%	8.5%	24.8%
Alicon Castalloy Ltd	-4.9%	3.7%	44.3%
Premier Explosives Ltd	-2.2%	-7.5%	20.8%
Gufic Biosciences Ltd	8.8%	37.7%	105.6%
Excel Industries Ltd	23.0%	47.8%	72.7%
Vesuvius India Ltd	-7.3%	1.9%	15.0%
Munjal Showa Ltd	-3.5%	-1.5%	43.3%
Bharat Rasayan Ltd	32.6%	25.7%	106.4%
Alkyl Amines Chemicals Ltd	2.5%	19.3%	84.6%
Grauer and Weil (India) Ltd	16.4%	37.8%	108.1%
Texmaco Rails & Engineering Ltd	3.5%	25.7%	10.3%
Nagarjuna Agrichem Ltd	-1.3%	-4.4%	91.5%
Simplex Infrastructures Ltd	10.8%	27.6%	93.9%
Sadhana Nitrochem Ltd	4.7%	6.8%	185.2%
ITD Cementation India Ltd	9.2%	22.2%	42.7%
Westlife Development Ltd	41.4%	54.0%	111.5%
Federal Mogul Goetze (India) Ltd	7.5%	3.0%	6.6%
Cupid Limited	-2.3%	-8.9%	-15.6%
Dynamatic Technologies Ltd	-2.4%	-16.7%	-30.9%
Hitech Corporation Ltd	-7.1%	-11.2%	2.2%
NRB Bearings Ltd	3.3%	24.7%	32.5%
Indian Hume Pipe Co. Ltd	-11.1%	-23.0%	4.1%
Engineers India Ltd	-3.0%	14.9%	19.5%
TRIL	8.0%	9.6%	-2.0%
Gulshan Polyols Ltd	-3.0%	-7.9%	1.1%
Nesco	0.8%	-8.7%	33.4%

Weekly Sectoral Gainers & Losers in (%)



The week that went by:

The equity benchmarks started the week on a positive note. The markets opened mildly lower following the tepid Asian markets. There is more of a cautious attitude among the investors with the various economic indicators lined up in the week. The markets extended its losses for the mid-week opening with the investors remaining cautious of the RBI policy decision. After the negative closing post the decision of maintaining the rates unchanged by the RBI, the markets bounced back after the short covering of beaten stocks.

Coverage Universe Valuations												
Company	Reco	Reco at	CMP	Tgt price	Upside	Mcap	EPS		PE(x)		EV/EBITDA (x)	
		(Rs)	(Rs)	(Rs)	(%)		(Rs bn)	FY17	FY18E	FY17	FY18E	FY17
Supreme Petrochem Ltd	BUY	77	367	500	37.0	35.2	18.6	19.9	19.6	18.4	11.5	10.9
Shanthi Gears Ltd	BUY	107	139	200	40.3	11.7	2.8	3.1	51.8	46.2	32.7	28.7
Hind Rectifiers Ltd	BUY	69	122	175	49.7	1.8	-4.5	0.5	-110.2	230.2	44.5	30.0
KCP Limited	BUY	71	122	150	24.7	15.5	3.6	4.6	53.1	33.0	12.9	11.1
Harita Seating System Ltd	BUY	266	919	1150	25.3	7.1	32.4	34.5	28.3	26.6	25.9	21.7
Hester Biosciences Ltd	BUY	565	1176	1500	4.8	12.2	29.2	34.2	49.0	48.3	30.3	25.8
Rallis India Ltd	BUY	181	240	300	26.5	46.1	15.3	11.2	26.6	21.1	17.6	14.8
The Hitech Gears Ltd	BUY	298	414	600	16.5	9.7	10.9	11.1	47.4	47.2	20.0	17.6
Bharat Bijlee Ltd	BUY	787	1128	2000	83.2	6.2	34.7	39.3	31.5	27.8	42.8	25.8
Castrol India Ltd	BUY	447	401	550	38.5	196.5	14.4	14.9	27.6	26.9	17.3	16.9
Tamil Nadu Newsprint & Papers Ltd	BUY	224	364	450	17.1	26.7	38.2	36.6	10.1	10.5	21.5	20.5
Triveni Turbines Ltd	BUY	92	134	175	34.1	0.4	3.5	3.6	37.1	36.0	26.3	24.7
Siemens Ltd	BUY	1128	1171	1500	27.7	418.1	9.1	10.0	129.2	117.7	39.4	88.2
Hikal Ltd	BUY	143	236	325	37.8	19.4	8.1	8.7	29.0	27.2	12.0	11.0
Aksh Optifibre Ltd	BUY	15	32	45	43.3	5.1	3.4	5.5	9.2	5.7	6.1	4.4
GMM Pfäudler Ltd	BUY	332	660	800	18.5	9.9	19.3	21.1	35.0	32.0	24.0	21.9
Alicon Castalloy Ltd	BUY	288	578	750	33.9	6.9	21.4	24.1	26.2	23.2	10.3	9.2
Premier Explosives Ltd	BUY	350	394	525	46.9	3.6	16.6	15.3	24.6	26.7	13.9	11.3
Gufic Biosciences Ltd	BUY	50	95	100	5.3	7.3	1.5	2.0	64.5	47.6	29.0	22.1
Excel Industries Ltd	BUY	380	642	800	23.9	8.3	35.8	25.1	18.1	25.7	20.8	13.4
Vesuvius India Ltd	BUY	1165	1189	1500	23.0	24.4	49.0	65.0	24.9	18.8	13.5	10.9
Munjal Showa Ltd	BUY	191	266	300	10.1	10.9	14.1	15.1	19.3	18.0	11.5	11.0
Bharat Rasayan Ltd	BUY	2747	3856	4250	15.7	15.4	128.1	141.2	28.7	26.0	15.2	13.7
Alkyl Amines Chemicals Ltd	BUY	391	579	700	20.5	11.9	24.3	29.2	23.9	19.9	14.0	13.4
Grauer and Weil (India) Ltd	BUY	45	70	80	13.1	16.0	2.3	2.3	31.3	30.2	17.8	17.4
Texmaco Rails & Engineering Ltd	BUY	91	121	170	45.5	20.2	1.5	2.7	76.3	43.4	49.2	30.3
Nagarjuna Agrichem Ltd	BUY	29	46	60	36.8	6.8	2.3	0.9	18.9	50.0	14.4	13.3
Simplex Infrastructures Ltd	BUY	540	575	700	22.0	20.2	24.3	30.5	23.6	18.8	5.6	4.8
Sadhana Nitrochem Ltd	BUY	67	71	100	35.1	0.7	2.5	5.5	30.0	13.4	11.2	9.0
ITD Cementation India Ltd	BUY	158	206	225	7.3	32.5	4.8	2.9	43.7	71.8	15.6	21.9
Westlife Development Ltd	BUY	266	348	425	16.0	57.0	-0.8	0.3	-469.6	1073.1	125.1	75.5
Federal Mogul Goetze (India) Ltd	BUY	540	520	750	40.7	29.7	12.9	15.7	41.2	33.9	17.0	15.4
Cupid Limited	BUY	286	270	340	30.1	2.9	18.5	23.4	14.1	11.2	8.4	7.1
Dynamatic Technologies Ltd	BUY	2160	2030	3000	48.1	12.8	23.0	30.4	52.7	67.7	11.2	11.1
Hitech Corporation Ltd	BUY	175	171	230	38.6	2.9	6.9	7.2	25.4	24.2	9.7	8.5
NRB Bearings Ltd	BUY	138	147	200	34.8	14.4	5.3	5.5	26.4	25.0	15.0	14.4

*Castrol, Vesuvius, ITD Cementation- Dec Ending | Siemens-Sept ending|

Recommendations adjusted as per Corporate Actions						
Company	Reco	Target	Corp Action	Adj Price	Adj Tgt Price	Appreciation
IHP Ltd	341	600	Bonus 1 : 1.	171	600	152%
Engineers India Ltd	211	200	Bonus 1 : 1.	106	200	74%
Transformers and Rectifiers (India) Ltd	300	450	Stock Split from Rs.FV 10 to Rs.FV 1.	30	40	15%
Gulshan Polyols Ltd	390	500	Stock Split from Rs.FV 5 to Rs.FV 1.	78	110	2%
Nesco Ltd	2397	3200	Stock Split from Rs.FV 10 to Rs.FV 2.	479	640	9%

Coverage Universe Valuations												
Company	Reco	Adj Reco	CMP	Tgt price	Upside	Mcap	EPS		PE(x)		EV/EBITDA (x)	
		(Rs)	(Rs)	(Rs)	(%)		(Rs bn)	FY17	FY18E	FY17	FY18E	FY17
IHP Ltd	BUY	171	494	600	39.8	20.8	18.4	25.5	23.4	16.8	40.3	43.6
Engineers India Ltd	BUY	106	181	200	9.3	61.7	4.8	4.7	38.0	39.0	9.4	16.3
Transformers and Rectifiers (India) Ltd	BUY	30	33	40	16.4	0.5	4.9	4.9	3.5	2.3	4.9	4.9
Gulshan Polyols Ltd	BUY	78	80	110	38.4	3.7	5.9	6.4	13.4	12.4	8.1	7.1
Nesco Ltd	BUY	479	517	640	22.4	7.4	120.2	137.5	4.4	3.8	17.2	14.4

Coverage Performance Sheet										
Company	Reco at	CLS	Target Price (Rs)							Appreciation
	(Rs)	(Rs)	Target 1	Target 2	Target 3	Target 4	Target 5	Target 6	Target 7	(%)
Supreme Petrochem Ltd	77	365	120	150	200	275	350	500	-	374%
Shanthi Gears Ltd	107	143	150	200	-	-	-	-	-	33%
Hind Rectifiers Ltd	69	117	110	140	175	-	-	-	-	69%
KCP Limited	71	120	105	150	-	-	-	-	-	69%
Harita Seating System Ltd	266	918	400	600	750	900	1150	-	-	245%
Hester Biosciences Ltd	565	1432	750	875	1150	1500	-	-	-	153%
Rallis India Ltd	181	237	260	300	-	-	-	-	-	31%
The Hitech Gears Ltd	298	515	450	600	-	-	-	-	-	73%
Bharat Bijlee Ltd	787	1092	1100	1500	2000	-	-	-	-	39%
Castrol India Ltd	447	397	550	-	-	-	-	-	-	-11%
Tamil Nadu Newsprint & Papers Ltd	224	384	350	450	-	-	-	-	-	72%
Triveni Turbines Ltd	92	131	135	175	-	-	-	-	-	42%
Siemens Ltd	1128	1174	1500	-	-	-	-	-	-	4%
Hikal Ltd	143	236	200	250	325	-	-	-	-	65%
Aksh Optifibre Ltd	15	31	24	35	45	-	-	-	-	109%
GMM Pfaudler Ltd	332	675	500	700	800	-	-	-	-	103%
Alicon Castalloy Ltd	288	560	450	600	750	-	-	-	-	94%
Premier Explosives Ltd	350	408	450	525	-	-	-	-	-	17%
Gufic Biosciences Ltd	50	95	75	100	-	-	-	-	-	90%
Excel Industries Ltd	380	646	550	650	800	-	-	-	-	70%
Vesuvius India Ltd	1165	1220	1500	-	-	-	-	-	-	5%
Munjaj Showa Ltd	191	273	250	300	-	-	-	-	-	43%
Bharat Rasayan Ltd	2747	3674	3500	4250	-	-	-	-	-	34%
Alkyl Amines Chemicals Ltd	391	581	550	700	-	-	-	-	-	49%
Grauer and Weil (India) Ltd	45	71	65	80	-	-	-	-	-	57%
Texmaco Rails & Engineering Ltd	91	117	125	170	-	-	-	-	-	28%
Nagarjuna Agrichem Ltd	29	44	45	60	-	-	-	-	-	51%
Simplex Infrastructures Ltd	540	574	700	-	-	-	-	-	-	6%
Sadhana Nitrochem Ltd	67	74	100	-	-	-	-	-	-	10%
ITD Cementation India Ltd	158	210	225	-	-	-	-	-	-	33%
Westlife Development Ltd	266	366	350	425	-	-	-	-	-	38%
Federal Mogul Goetze (India) Ltd	540	533	750	-	-	-	-	-	-	-1%
Cupid Limited	286	261	340	-	-	-	-	-	-	-9%
Dynamatic Technologies Ltd	2160	2025	3000	-	-	-	-	-	-	-6%
Hitech Corporation Ltd	175	166	230	-	-	-	-	-	-	-5%
NRB Bearings Ltd	138	148	200	-	-	-	-	-	-	8%

*Castrol, Vesuvius, ITD Cementation- Dec Ending | Siemens-Sept ending |

Recommendations adjusted as per Corporate Actions						
Company	Reco	Target	Corp Action	Adj Price	Adj Tgt Price	Appreciation
IHP Ltd	341	600	Bonus 1 : 1.	171	600	152%
Engineers India Ltd	211	200	Bonus 1 : 1.	106	200	74%
Transformers and Rectifiers (India) Ltd	300	450	Stock Split from Rs.FV 10 to Rs.FV 1.	30	45	15%
Gulshan Polyols Ltd	390	500	Stock Split from Rs.FV 5 to Rs.FV 1.	78	140	2%
Nesco Ltd	2397	3200	Stock Split from Rs.FV 10 to Rs.FV 2.	479	640	9%

Calls Closed							
Company	Reco	Reco at	Closed price	Company	Reco	Reco at	Closed price
		(Rs)	(Rs)			(Rs)	(Rs)
KEC International Ltd	BUY	140	240	Mukand Engineers Ltd	BUY	33	56
Rajoo Engineers Ltd	BUY	15	30	Camlin Fine Chemicals Ltd	BUY	111	87
Omkar Speciality Chemicals Ltd	BUY	162	90	West Coast Paper Mills Ltd	BUY	67	187
Navneet Education Ltd	BUY	96	159	GEE Limited	BUY	33	44.5
MM Forgings Limited	BUY	607	856				

*Omkar: Spin off

Strong order book

Targets revised

Robust Numbers

On Recovery Mode

Subdued Quarter

Coverage News:

Transformers and Rectifiers (India) Limited:

The company has received order for 15No of transformers amounting to Rs127cr from Power Grid Corporation of India Limited.

Our comments:

The order book as on date stands at Rs937cr.

Target price revision:

Westlife development Limited:

We have revised the target to Rs425 from the earlier target of Rs350 which has been breached.

The Hi-tech Gears Limited:

We have revised the target to Rs600 from the earlier breached target of Rs450.

Result Update:

The Hi-tech Gears limited:

The net sales came in at Rs1,367mn as compared to Rs1,194mn in the same quarter last year, growth of 14.5%. The Ebidta margins grew to 13.5% as compared to 11.7% in the same quarter last year. The net profit clocked growth of 60.1% to Rs91mn as compared to Rs57mn in the comparative quarter. EPS for the quarter stood at Rs4.87.

Outlook and Recommendations:

The company has reported good set of numbers for the quarter under reference giving us the liberty to revise our projections upwards. We continue with our stance on the Indian auto components industry in the long run and maintain a BUY on the stock with a target of Rs450 for a time frame of 12 months.

Sadhana Nitrochem Limited:

The net sales came in at Rs159mn as compared to Rs132mn in the same quarter last year, growth of 20.1%. The Ebidta margins stood at 13.5%. The net profit came in at Rs8mn as compared to Rs0.1mn in the comparative quarter. EPS came in at Rs0.88

Outlook and Recommendations:

The company has started indicating a turnaround with strong topline and bottom-line numbers and steady margins. We maintain our stance with the target of Rs100 over a 12 months' horizon.

Indian Hume Pipes Limited:

The company reported net sales of Rs2,142mn (excluding GST) as against Rs4,330mn (including taxes) in the same quarter last year, de-growth of 50%. Despite the turnover being lower than the previous year, the Ebidta margins for the quarter under review stood at 11.7%. The net profit came in at Rs84mn as against R216mn, drop of 61%. The EPS for the quarter is Rs1.72 The balance value of orders in hand as on date is Rs3,248cr as against Rs2,831cr in the corresponding period of the previous year. As per the management presentation, the major stream of revenue comes from execution of drinking water projects. Pre-GST such contracts executed for Government were exempt from Service Tax, Excise Duty was exempt on Pipes and other material used in execution of these contracts and works contract tax / VAT of approximately 5% was applicable in most of the cases. On rollout of GST, these contracts were placed initially in 18% slab and with effect from 22nd August, 2017 in 12% slab. Customer base of the company is various State Governments and contracts were entered Pre-GST. Supplies from vendors were also affected due to GST implementation which has lead to transitional challenges, affecting execution of contracts in this quarter. The company has asked all its clients for carrying out necessary amendments and compensate for the additional tax liability.

Outlook and Recommendations:

The company has reported subdued results for the quarter under reference. This is mainly due to the cyclical nature of business and post effects of implementation of GST. Maintaining a positive on the outlook of the company going forward, we continue to recommend a BUY with a target price of Rs600.

Ratings Cut

ECONOMY:

Fitch Ratings cut India's FY18 GDP growth forecast to 6.7%

Fitch Ratings has cut the country's GDP growth forecast for the current fiscal to 6.7% from the earlier projected 6.9%, saying the rebound was weaker than expected. It also cut GDP growth forecast for 2018-19 fiscal year to 7.3% from 7.4% predicted in its September Global Economic Outlook (GEO). Fitch, however, expects GDP growth to pick up in the next two years on back of gradual implementation of the structural reform agenda and higher real disposable income.

Our comments:

Stating that it expects GDP growth to pick up in the next two years, Fitch said gradual implementation of the structural reform agenda is expected to contribute to higher growth, as will higher real disposable income.

Unchanged Repo Rate

RBI keeps repo rate unchanged at 6%, maintains neutral stance

The six-member Monetary Policy Committee (MPC) of the Reserve Bank of India (RBI) kept the short-term lending rate, also known as repo rate, unchanged at 6% in its fifth bi-monthly policy review of the fiscal year. The policy rate still stands at a seven year low. The committee had last cut the key lending rate by 25 basis points in August this year. The RBI also maintained its projection for FY18 real GVA growth at 6.7%, saying the risks are evenly balanced.

Our comments:

The RBI's policy stance was in line with expectations, maintaining a word of caution on the upside risks emanating from high commodity prices, global financial instability, HRA related increases, rising input costs and fiscal slippages. RBI's H2 inflation has been revised marginally higher even as it retained the GVA forecast of 6.7% against the expectation of 6.5%.

Healthy Indian Market

INDUSTRY:

Indian healthcare market to hit USD372bn by 2022

India's healthcare market may see threefold jump in value terms to USD372bn by 2022, driven by growing incidence of lifestyle diseases and rising demand for affordable healthcare delivery systems as per the report by ASSOCHAM. It also said the value of the sector in 2016 stood at USD110bn and will see a compounded annual growth rate (CAGR) of 22%. Besides, the medical devices market in India, which was valued at USD4bn as of 2016, is likely to cross USD11bn mark by 2022 on the back of growing geriatric population, uptick in medical tourism and gradual decline in cost of medical services.

Our comments:

Growing lifestyle diseases, rising demand for affordable healthcare delivery systems due to increasing healthcare costs, emergence of telemedicine, rapid health insurance penetration, mergers and acquisitions are helping to reach untapped markets and government initiatives are driving healthcare market in India.

*Fertilizers Subsidy
Reduced*

Fertiliser subsidy arrear drops to Rs 23,000 cr: Ananth Kumar

As per the latest updates from the fertiliser minister Mr. Ananth Kumar, the arrear for Fertiliser subsidy has been reduced to Rs23,000crore. There would more funds needed from the finance ministry to clear the backlog completely. He also added, the direct benefit transfer (DBT) for fertiliser subsidy which is also implemented in some states, will be rolled out across the country from April 1. The backlog of the subsidy which was Rs44,000 crore (in 2014) has been reduced to Rs23,000 crore. The minister also mentioned, that he would be requesting the finance minister to clear this arrear in one go.

Our comments:

These steps as a whole will benefit, the states, industry as well as the rural producers.

Wipro V/s US Utility firm

COMPANY:

Wipro to contest lawsuit filed by US utility firm

Wipro said it would contest a USD140mn (Rs910cr) lawsuit filed by its US-based customer National Grid US over an Enterprise Resource Planning (ERP) project. National Grid US has filed a case in the US District Court for the Eastern District of New York, seeking USD40mn plus additional costs relating to the project, which it joined in 2010 as per the company. The five-year project, which began in 2009, was implemented by 2014.

Our comments:

Refuting the allegations of the electric utility firm, Wipro said though National Grid had been its valued customer over the years in the US and Britain, it believed that its client's misstate facts and claims were baseless.

Nod for Biosimilars

Biocon receives USFDA nod for biosimilar

Biocon said that the US drug regulator approved Mylan and Biocon's Ogivri, biosimilar for the treatment of HER2-positive breast and gastric cancers, Ogivri has been approved for all indications included in the label of the reference product, Herceptin, including for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer. Ogivri is the first USFDA-approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon's joint portfolio approved in the US. Mylan anticipates potentially being the first company to offer a biosimilar to Herceptin, as a result of Mylan's ability to secure global licenses for its trastuzumab product from Genentech and Roche earlier this year. This milestone secured a clear pathway to commercialize Mylan's biosimilar to Herceptin in various markets globally.

Our comments:

Mylan and Biocon are exclusive partners on a broad portfolio of biosimilar and insulin products.

Consolidation in the Education sector

Zee Learn may pick up 42.78% in MT Educare

Zee Learn is in talks with MT Educare that runs the popular Mahesh Tutorials coaching classes, to buy a controlling stake in the company, in a growing sign that a wave of fresh capital is triggering larger consolidation in the educational services space. As per sources, Zee initially plans to buy the entire promoter block of 42.78% and will make an open offer for another 20% stake. At current valuations, Zee will have to pay Rs140cr for a controlling stake in the company.

Our comments:

Zee Media has had multiple rounds of formal negotiations with MT Educare management. A transaction is highly likely before fiscal-end as indicated by sources.

DRVR partners Tata Comm.

Thai start-up DRVR partners with Tata Communications

International fleet management application provider, DRVR has selected Tata Communications as its global IoT connectivity partner to help achieve its objective of making Asia's vehicle fleets the smartest and most cost-efficient in the world.

Our comments:

This is a positive for the company.

Orders for Reliance Infra

Reliance Infrastructure secures two EPC contracts worth Rs5000cr

Reliance Infrastructure has won two prestigious EPC contracts in Bangladesh together valued at Rs5,000cr. The projects were won on International Competitive Bidding (ICB). The first EPC contract includes setting up the entire infrastructure of a 750 MW LNG-based combined cycle power plant at Meghnaghat (Dhaka) while the second project is for building a 500 MMSCFD floating storage re-gasification unit (FSRU) based integrated LNG terminal project at Kutubdia Island, both in Bangladesh. Both the contracts are to be executed in a project schedule of 24 months, and are to be completed by 2019. The contracts for both the projects entail design, engineering, supply, transportation, erection, testing and commissioning processes.

Our comments:

This is an addition to the order backlog of the company.

Patents for Suven Life

More Orders for L&T

COMPANY:

Suven Life Sciences secures product patents in Eurasia and Norway

Suven Life Sciences has secured one product patent from Eurasia and one product patent from Norway corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and that these Patents are valid through 2034 and 2026 respectively. The granted claims of the patents include the class of selective 5-HT6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

Our comments:

The company has huge global market potential for cognitive disorders with high unmet medical needs, hence it has a pipeline of molecules in CNS arena. The volumes are further expected to increase in this segment after the above patent approval.

L&T's Hydrocarbon Engineering arm awarded order worth Rs1,600cr

L&T Hydrocarbon Engineering Ltd (LTHE), a wholly owned subsidiary of Larsen & Toubro Limited, has won an order worth over Rs1,600cr from Hindustan Petroleum Corporation Limited, Visakhapatnam refinery. The project is a part of HPCL Visakh Refinery Modernisation Project (VRMP) and involves Engineering, Procurement, Construction and Commissioning of 3.053 MMTPA Full Conversion Hydrocracker Project.

Our comments:

The order reinforces L&T's unique capability to deliver 'design to build' engineering and construction solutions across the hydrocarbon spectrum.

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE). PSBPL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Retail), commodity broking, depository participant, and financial products like mutual funds.

PSBPL is SEBI registered under SEBI (Research Analysts) Regulations, 2014 (SEBI Registration no- INH00000859). PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

News has been sourced from various leading newspaper articles for reference.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

PSBPL or its associates may have financial interest in the subject company.

Research Analyst or his/her relative's financial interest in the subject company. (YES/NO)-NO

PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

PSBPL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: (YES/NO)- NO

PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

The research Analyst has served as officer, director or employee of the subject company : (YES/NO)-NO

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.